10.6084/m9.figshare.9962852.v1
Xiaohong Han
Xiaohong
Han
Ying Han
Ying
Han
Qiaoyun Tan
Qiaoyun
Tan
Yu Huang
Yu
Huang
Jianliang Yang
Jianliang
Yang
Sheng Yang
Sheng
Yang
Xiaohui He
Xiaohui
He
Shengyu Zhou
Shengyu
Zhou
Yan Song
Yan
Song
Jinping Pi
Jinping
Pi
Lijie Zuo
Lijie
Zuo
Jiarui Yao
Jiarui
Yao
Di Wu
Di
Wu
Zhishang Zhang
Zhishang
Zhang
Yuankai Shi
Yuankai
Shi
MOESM9 of Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy
Springer Nature
2019
CtDNA
Efficacy
Chemotherapy
Lung adenocarcinoma
2019-10-10 08:55:24
Journal contribution
https://springernature.figshare.com/articles/journal_contribution/MOESM9_of_Tracking_longitudinal_genetic_changes_of_circulating_tumor_DNA_ctDNA_in_advanced_Lung_adenocarcinoma_treated_with_chemotherapy/9962852
Additional file 9: Fifure S4. Landscape of potentially clinically actionable variants in plasma of LUAD. (A)Number of individuals for targeting therapy during chemotherapy and mutated frequency of genes. Pre (goldenrod1): patients have potential drug targets only in pre chemotherapy; Pre & Post (grey): patients have potential drug targets in pre and post chemotherapy; Post (indianred): patients have potential drug targets only in post chemotherapy). Each bar represented a category. (B) Number of individuals for targeting therapy, each bar represented a gene. (C) Variants in genes (rows) that may predict sensitivity to ERK-Signalling, PI3K/MTOR inhibitor. Vertical columns correspond to plasma samples.